A Study to Investigate the Safety and Efficacy of UC-MSCs in Pediatric Patients With Cerebral Palsy

  • End date
    Jul 27, 2023
  • participants needed
  • sponsor
    Rohto Pharmaceutical Co., Ltd.
Updated on 27 September 2021


UDI-001 is administered to pediatric patients with cerebral palsy attributed to periventricular leukomalacia (PVL) multiple times to investigate its safety and efficacy.


This is the first study of UDI-001 to be administered to children. Pediatric patients with cerebral palsy attributed to PVL are enrolled to the study and umbilical cord derived mesenchymal stromal cells (UC-MSCs) are administered to those patients multiple times intravenously. Safety and efficacy of UC-MSCs are evaluated for 52 weeks after the first administration.

Condition Cerebral Palsy (Pediatric), Periventricular leukomalacia, cerebral palsy (cp), Cerebral Palsy
Treatment UDI-001
Clinical Study IdentifierNCT04873752
SponsorRohto Pharmaceutical Co., Ltd.
Last Modified on27 September 2021


Yes No Not Sure

Inclusion Criteria

Age >= 12 months and < 24 months corrected age at the time of informed consent
Diagnosed with cerebral palsy
Diagnosed with PVL
GMFCS level between II and IV
Able to obtain written informed consent from parents (legal representative)

Exclusion Criteria

Presence of progressive neurological disease
Presence of congenital anomaly
Diagnosed with Grade 3 or more severe intraventricular hemorrhage
Body weight < 5kg
Profound intellectual disorder
Complication of serious infection such as sepsis
Requirement of mechanical ventilation
Complication of serious organ failure such as kidney, liver or heart diseases or others and considered to be inappropriate
Diagnosed with or suspected of hypsarrhythmia
Positive for HBV, HCV, HIV or HTLV-1
Patients who have received cell therapy
Patients who have undergone selective dorsal rhizotomy or received botulinum toxin products within a certain period of time
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note